Optimizing ART and Other Interventions to Improve Health Outcomes for Women Living With HIV: Global Expert Perspectives
  • CME
  • CE

In this interactive video module, CCO’s expert faculty review and discuss the latest ART guidelines and key strategies and considerations for providing patient-centered care to women of childbearing age who are living with HIV in resource-limited settings.
Susan Cu-Uvin, MD
Program Director
Linda-Gail Bekker, FCP(SA), PhD
Nelly Mugo, MBChB, MMed, MPH
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: March 17, 2020 Expiration: March 16, 2021
Multimedia Optimizing ART and Other Interventions to Improve Health Outcomes for Women Living With HIV: Global Expert Perspectives
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME/CE posttest and evaluation.
Introduction and Overview (6 mins)
Watch an overview of the activity, review the latest data on the global burden of HIV infection among women, and consider how biologic, social, and economic factors contribute to the cycle of HIV transmission between men and women.
Launch Introduction and Overview (6 mins)
Case 1: Contraception and ART (14 mins)
Consider the case of a young woman receiving a recommended ART regimen and seeking effective contraception that is compatible with her HIV treatment. Watch as experts discuss the importance of determining reproductive intentions, the impact of unintended pregnancy on HIV and ART outcomes for women, the benefits of long-acting contraceptives, the relative efficacy of long-acting contraception options, and key drug–drug interactions between ART and contraceptives.
Launch Case 1: Contraception and ART (14 mins)
Case 1 Continued: ART Considerations (15 mins)
Consider recent data on weight gain differences among ART regimens and gain a better understanding of the full spectrum of sexual and reproductive health services that should be offered to all women living with HIV
Launch Case 1 Continued: ART Considerations (15 mins)
Case 2: Initial ART Selection When Planning Pregnancy (7 mins)
Review the latest guideline recommendations and supporting data on the safety of ART at the time of conception and during early pregnancy.
Launch Case 2: Initial ART Selection When Planning Pregnancy (7 mins)
Case 2 Continued: Safe Conception for Woman in Serodiscordant Relationship (11 mins)
Learn about the varied options for safe conception among couples who are HIV serodiscordant, including the power of U = U evidence and messaging and the role of PrEP as part of a transmission prevention package in this setting.
Launch Case 2 Continued: Safe Conception for Woman in Serodiscordant Relationship (11 mins)
Pregnancy Outcomes for Women With HIV (8 mins)
Reflect on data from the IMPROVE study comparing rates of adverse pregnancy outcomes among women with vs without HIV and consider how these findings underscore the critical importance of early, comprehensive interventions to support safe conception and optimize antenatal care and overall health of women of childbearing potential who are living with HIV.
Launch Pregnancy Outcomes for Women With HIV (8 mins)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply new data and guideline updates in the selection of ART for women of childbearing age
  • Optimize ART for women of childbearing age based on individual patient factors
  • Develop strategies to address the unique needs of women living with HIV, including contraception considerations, cervical cancer screening, and engagement in care

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by
Merck & Co., Inc.
ViiV Healthcare

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Susan Cu-Uvin, MD

Professor, OB-GYN and Medicine
Brown University
Attending, Infectious Diseases/HIV
The Miriam Hospital
Providence, Rhode Island

Susan Cu-Uvin, MD, has no relevant conflicts of interest to report.

Faculty

Linda-Gail Bekker, FCP(SA), PhD

Chief Operating Officer
Desmond Tutu HIV Foundation
Deputy Director
Desmond Tutu HIV Centre
Immediate Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town,
Cape Town, South Africa

Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD, has no relevant conflicts of interest to report.
Nelly Mugo, MBChB, MMed, MPH

Head, Sexual Reproductive Adolescent Child Health Research Program
Centre for Clinical Research
Kenya Medical Research Institute (KEMRI)
Nairobi, Kenya

Nelly Mugo, MBChB, MMed, MPH, has no relevant conflicts of interest to report.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who provide care for women with HIV infection.

Goal

The goal of this activity is to improve participants’ competence in providing optimal ART management for women of childbearing age living with HIV.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-040-H02-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 17, 2020, through March 16, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert-authored CCO slides on optimizing treatment for patients with HIV, featuring patient cases and evolving considerations for ART management

Monica Gandhi, MD, MPH
Program Director
Linda-Gail Bekker, FCP(SA), PhD Pedro Cahn, MD, PhD Laura Waters, FRCP, MD
Released: July 13, 2020

April 2020 data from Tsepamo study on NTD prevalence following dolutegravir and other ART exposure at conception from AIDS 2020 reported by CCO

Released: July 11, 2020

Data from AIDS 2020: Virtual on Week 48 metabolic changes (lipids, insulin resistance) after switch from TAF-based ART to DTG/3TC in TANGO, reported by CCO

Released: July 11, 2020

HPTN 083 data from AIDS 2020: Virtual on long-acting injectable cabotegravir vs daily TDF/FTC for PrEP in MSM and transgender women, reported by CCO

Released: July 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?